rituximab

(pharmacology) A chimeric monoclonal antibody (trademark Rituxan) administered by intravenous injection especially to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia by binding to the protein CD20 found on the surface of B cells and causing their lysis.